Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients

Blood

Volumn 117, Issue 3, 2011, Pages 936-941

  Guo, Mei ^a   Hu, Kai Xun ^a   Yu, Chang Lin ^a   Sun, Qi Yun ^a   Qiao, Jian Hui ^a   Wang, Dan Hong ^a   Liu, Guang Xian ^a   Sun, Wan Jun ^b   Wei, Li ^a   Sun, Xue Dong ^a   Huang, Ya Jing ^b   Qiao, Jun Xiao ^b   Dong, Zheng ^a   Ai, Hui Sheng ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Second Artillery General Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; HLA MATCHING; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MICROCHIMERISM; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; THROMBOCYTE; TREATMENT OUTCOME;

EID: 78751680036     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-288506     Document Type: Article

References (33)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062.
2. Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747-4753.
3. Olivieri A, Capelli D, Troiani E, et al. A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. Exp Hematol. 2007;35(7):1074-1082. (Pubitemid 46921303)
4. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1):63-73. (Pubitemid 43996625)
5. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903.
6. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
7. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302-1311.
8. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332(25):1678-1683.
9. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103(2):479-485. (Pubitemid 38140076)
10. Slavin S, Nagler A, Naparstek A, et al. Nonmyeloblastive stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic disease. Blood. 1998;91(3):756-763. (Pubitemid 28078275)
11. Estey E, Lima MD, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109(4):1395-1400. (Pubitemid 46239569)
12. Ai HS, Huang XJ, Qiao ZH, et al. Muticenter report of nonmyeloablative allogeneic stem cell transplantation for hematologic diseases. Zhonghua Xue Ye Xue Za Zhi. 2009;30(8):505-508.
13. Spitzer TR. Haploidentical stem cell transplantation: The always present but overlooked donor. Hematology Am Soc Hematol Educ Program. 2005:390-395.
14. Shimazaki C, Ochiai N, Uchida R, et al. Non-T-cell-depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism. Blood. 2003;101(8):3334-3336. (Pubitemid 36858033)
15. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.
16. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 1996;87(6):2195-2204. (Pubitemid 26086858)
17. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood. 2006;107(9):3430-3435.
18. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. J Immunother. 1998;21(6):447-453. (Pubitemid 28493716)
19. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
20. Yano Y, Hara M, Miyahara T, et al. Microchimeric cells from the peripheral blood associated with cardiac grafts are bone marrow derived, long-lived and maintain acquired tolerance to minor histocompatibility antigen H-Y. Transplantation. 2001;71(10):1456-1462. (Pubitemid 32507121)
21. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
22. Marshall NA, Howe JG, Formica R, et al. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation. Blood. 2000;96(8):2814-2821.
23. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100. (Pubitemid 34229476)
24. Medina DJ, Gharibo M, Savage P, et al. A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leuk Res. 2008;32(12):1842-1848.
25. Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17(4):1234.
26. Strair RK, Schaar D, Medina D, et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol. 2003;21(20):3785-3791. (Pubitemid 46606233)
27. Fischer JC, Ottinger H, Ferencik S, et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol. 2007;178(6):3918-3923. (Pubitemid 46417662)
28. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236-242.
29. Guo M, Sun Z, Sun QY, et al. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Biol Blood Marrow Transplant. 2009;15(8):930-937.
30. Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med. 2008;358(4):369-374. (Pubitemid 351159236)
31. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008;358(4):353-361. (Pubitemid 351159234)
32. Ueno NT, Cheng YC, Rondón G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102(10):3829-3836. (Pubitemid 37409408)
33. Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002;30(6):367-373. (Pubitemid 35203509)